|
STARD3NL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73190350949426E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.65090007909453E-10 |
| Normal-vs-Stage2 |
1.757940E-04 |
| Normal-vs-Stage3 |
4.3521997117324E-10 |
| Normal-vs-Stage4 |
1.91250004721866E-09 |
| Stage1-vs-Stage2 |
6.168400E-01 |
| Stage1-vs-Stage3 |
8.634200E-02 |
| Stage1-vs-Stage4 |
3.966500E-02 |
| Stage2-vs-Stage3 |
1.209400E-01 |
| Stage2-vs-Stage4 |
4.945600E-02 |
| Stage3-vs-Stage4 |
4.995000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.89042140117135E-12 |
| Normal-vs-AfricanAmerican |
5.456400E-02 |
| Normal-vs-Asian |
9.10499997619496E-09 |
| Caucasian-vs-AfricanAmerican |
1.939680E-02 |
| Caucasian-vs-Asian |
2.824200E-01 |
| AfricanAmerican-vs-Asian |
2.233800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.47840020412605E-10 |
| Normal-vs-Female |
2.15710005413428E-10 |
| Male-vs-Female |
6.379800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62059999975206E-07 |
| Normal-vs-Age(41-60Yrs) |
5.16960030338964E-10 |
| Normal-vs-Age(61-80Yrs) |
2.66830002537688E-09 |
| Normal-vs-Age(81-100Yrs) |
6.097700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.189000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.303900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.950600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.120800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.595000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.966800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.860000E-02 |
| Classical-VS-Follicular |
2.583800E-01 |
| Classical-VS-Other |
8.408200E-01 |
| Classical-VS-Normal |
1.53729999952112E-07 |
| Tall-VS-Follicular |
1.738050E-02 |
| Tall-VS-Other |
5.080200E-01 |
| Tall-VS-Normal |
1.08259999853644E-08 |
| Follicular-VS-Other |
6.088200E-01 |
| Follicular-VS-Normal |
1.246880E-04 |
| Other-VS-Normal |
2.075700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02969999193903E-09 |
| Normal-vs-N1 |
2.01280000444726E-08 |
| N0-vs-N1 |
1.477750E-01 |
|
|
